The present invention is directed to therapeutic compounds treatment methods and kits affecting the NCCa-ATP channel of neural tissue including neurons glia and blood vessels within the nervous system and methods of using same.The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia and is regulated by the sulfonylurea receptor SUR1 being inhibited by sulfonylurea compounds e.g. glibenclamide and tolbutamide and opened by diazoxide.Antagonists of the NCCa-ATP ch...

The present invention is directed to therapeutic compounds treatment methods and kits affecting the NCCa-ATP channel of neural tissue including neurons glia and blood vessels within the nervous system and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia and is regulated by the sulfonylurea receptor SUR1 being inhibited by sulfonylurea compounds e.g. glibenclamide and tolbutamide and opened by diazoxide. Antagonists of the NCCa-ATP ...

The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited by sulfonylurea compounds, e.g., glibenclamide and tolbutamide, and opened by diazoxide. Antagonists of the...

A polymeric construct is disclosed. The construct comprises a polysaccharide polymer having a selected medicament associated therewith. The medicament th us present is provided in a slow release form. lt;SDOCL LA=ENgt; 18 We Claim 1. A polymeric construct comprising a polysaccharide polymer having a selected medicament entrapped therewithin. 2. The construct as defined in claim 1 wherein said polymer is selected from the group consisting of alginic acid or a pharmaceutically acceptable salt ther...

The present invention is directed to therapeutic compounds treatment methods and kits affecting the NCca-ATP channel of neural tissue including neurons glia and blood vessels within the nervous system and methods of using same. The NCca-ATP channel is newly expressed in neural tissue following injury such as ischemia and is regulated by the sulfonylurea receptor SURl being inhibited by sulfonylurea compounds e.g. glibenclamide and tolbutamide and opened by diazoxide. Antagonists of the NCca-ATP ...

In the present invention there is disclosed a pharmaceutical combination containing 2 to 8 mg of 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidine-24-dione (compound of the general formula I) or a tautomeric form and/or pharmaceutically acceptable derivative thereof and sulfonylurea wherein the sulfonylurea is represented by glibenclamide glipizide gliclazide glimepiride tolazamide or tolbutamide. There is also disclosed the use of the above-described combination in a pharmaceutica...

A composition comprising a novel Ca2+-activated [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion which causes severe cell depolarization followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited by su...

A composition comprising a novel Ca<2+>-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited...

NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, an...